Sabbin bayanai kan maganin rigakafin cutar Hepatitis B da C

Kimiyyar Gileyad a yau ta ba da sanarwar bayanai daga bincike da yawa da ke nuna fa'idar asibiti da bambance-bambancen maganin cutar hanta, da kuma ci gaba da jajircewar Gileyad kan binciken hanta don ci gaba da kawar da cutar hanta ta kwayar cuta a Asiya. Ana gabatar da bayanan a taron 31st na Ƙungiyar Asiya ta Pacific don Nazarin Hanta (APASL 2022), Maris 30 - Afrilu 3, 2022 a Seoul, Koriya ta Kudu.    

"Bayanan asibiti daga karatunmu suna ƙarfafa ingantaccen ingantaccen inganci da bayanan aminci na jiyyanmu da yuwuwar fa'idar asibiti ga mutanen da ke zaune tare da hepatitis B da C. Waɗannan bayanan ƙarfafawa na iya ƙara tallafawa masu samar da lafiya wajen yin zaɓin magani mai dacewa ga marasa lafiya na hepatitis. a Asiya." In ji Betty Chiang, mataimakiyar shugabar harkokin kiwon lafiya, na kasa da kasa, Kimiyyar Gileyad.

Bayanai daga uku tenofovir (TFV) - tushen binciken don maganin ciwon hanta B (HBV) da aka gabatar a taron ya nuna cewa a lokacin da aka fara jiyya wasu marasa lafiya da ke fama da ƙananan haɗarin ciwon hanta (HCC) sun ci gaba zuwa haɗari mafi girma, yayin da yawancin matsakaici- ko babba. -masu haɗari sun inganta zuwa ƙananan haɗarin HCC bayan dogon lokaci na TFV.  

Bayanai daga nazarin 2 na Phase 3 na TFV disoproxil fumarate (TDF) vs. TDF / emtricitabine (FTC) a cikin marasa lafiya marasa lafiya (IT) da kuma nazarin Phase 5 guda biyu, kwatanta tenofovir alafenamide (TAF) vs. TDF a cikin rigakafi-active (IA) ) An yi amfani da marasa lafiya don samar da ƙimar haɗari na HCC ta amfani da Modified PAGE-B (mPAGE-B), kayan aiki don tsinkaya hadarin HCC na 0-shekara (ƙananan haɗari [8-≤9], matsakaici-haɗari [12-13], da babban haɗari [≥XNUMX]). 

Daga cikin marasa lafiya na 126 IT, 106 (84%), 19 (15%) da 1 (0.8%) sun kasance ƙananan, matsakaici, ko babban haɗari, bi da bi a asali. A mako na 192, yawancin sun kasance ba su canzawa ko ingantawa. Babu marasa lafiyar IT da suka haɓaka HCC. Daga cikin marasa lafiya na 1,631 IA (1,092 TAF; 539 TDF-> TAF), 901 (55%), 588 (36%), da 142 (9%) sun kasance ƙananan-, matsakaici-, ko babban haɗari, bi da bi a asali. A mako na 240, yawancin sun kasance ba su canza ba ko inganta; kawai 22 (2%) marasa lafiya sun koma haɗari mafi girma. Gabaɗaya, shari'o'in 22 HCC sun haɓaka (0.2%, 1.2%, da 9.2% a cikin ƙananan-, matsakaici, da ƙungiyoyi masu haɗari a asali).

Ƙarin bayanan da aka gabatar a taron yana ba da ƙima na ƙashin lafiya na ƙashi da na koda na TAF a duk tsarin ci gaban asibiti na Gileyad TAF HBV. Bayanai daga marasa lafiya 1,911 da aka bi da su tare da TAF ko TDF an bincika kuma a cikin nau'ikan masu haƙuri na HBV da yawa, gami da waɗanda ke cikin haɗarin ƙashi mai alaƙa da TDF da / ko guba na koda. An lura da kwanciyar hankali ko ingantattun sigogi na ƙashi da na koda tare da maganin TAF idan aka kwatanta da maganin TDF.

A cikin ciwon hanta na C, binciken da aka yi na Phase 3b wanda ke kallon jiyya-naïve da jiyya-jiyya na ciwon hanta na C (CHC) marasa lafiya a Koriya ya nuna cewa jiyya tare da sofosbuvir / velpatasvir da sofosbuvir / velpatasvir / voxilaprevir sun sami babban ci gaba na virological amsa ba tare da wani magani virologic ba. kasawa ko abubuwan da suka shafi jiyya mai tsanani. A cikin wani binciken da ke kimanta yuwuwar hulɗar miyagun ƙwayoyi da ƙwayoyi (DDI) a cikin marasa lafiya na Koriya ta CHC ta yin amfani da maganin rigakafi kai tsaye da ake samu, sofosbuvir / velpatasvir ya nuna kyakkyawan bayanin martabar DDI duk da yawan ƙimar haɓakawa da abubuwan ban dariya a cikin yanayin tsufa na yawan mutanen CHC a Koriya.